Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8IUC6
UPID:
TCAM1_HUMAN
Alternative names:
Proline-rich, vinculin and TIR domain-containing protein B; Putative NF-kappa-B-activating protein 502H; Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta
Alternative UPACC:
Q8IUC6; B3Y691; O75532; Q86XP8; Q96GA0
Background:
TIR domain-containing adapter molecule 1 (TICAM1) plays a pivotal role in innate immunity, acting as an adapter for TLR3, TLR4, and TLR5 to trigger NF-kappa-B and IRF activation, and induce apoptosis. It is crucial in mediating immune responses against pathogens, through recruitment of effector proteins leading to transcription factors activation and type I interferon expression.
Therapeutic significance:
Given its involvement in the immune response to human herpesvirus 1 (HHV-1) and its association with encephalopathy, acute, infection-induced, 6, herpes-specific, understanding the role of TICAM1 could open doors to potential therapeutic strategies for this rare but severe condition.